MedTrace Logo

Lesion Load and Location in Relation to Cognition, Fatigue and Physical Disability in RRMS

NCT05604092 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 63

Last updated 2022-11-03

No results posted yet for this study

Summary

In relapsing remitting multiple sclerosis (RRMS) the relationship between cognitive impairment (CI), fatigue and physical disability with white matter lesion load (WM-LL), location among other volumetric measures using automated platforms is still unclear.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DIAGNOSTIC_TEST

VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)

VolBrain, a fully automated platform that uses anonymized compressed NIFTI files to generate the volumetric data. Volbrain is increasingly recognized and compared to other volumetric tools. LesionBrain is a pipeline to automatically segment WM-L from T1 and FLAIR data. Number of lesions, absolute total lesion volume (in cubic cm), normalized lesion volume (percentage of total lesion volume to whole brain volume), lesion burden (percentage of total WM lesion volume to WM volume), and location (Periventricular, Juxtacortical, and Infratentorial) were obtained.

OTHER

Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

It includes the Symbol Digit Modalities Test (SDMT) for evaluating the information processing speed, the California Verbal Learning Test (CVLT-II) for evaluating verbal learning and memory, and the Brief Visual Memory Test (BVMT) for evaluating visual learning and memory. Cut off values were calculated as 1.5 SD below mean according to a group of healthy individuals who are matched in age, sex and education as following: 22 for SDMT, 38 for CVLT, and 10 for BVMTR

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Eman M Khedr, professor · Assuit university hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2022-08-31
Completion
2022-09-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05604092 on ClinicalTrials.gov